Why the "SAFE Drugs Act" Isn't Safe for Patients | Essential: The Pharmacy Compounding Podcast
About this episode
The episode discusses the implications of the proposed SAFE Drugs Act on compounding pharmacies and patient access to medications.
In this episode, Andrew Kantor is joined by federal lobbyist David Pore and PCCA's Amy Shank to examine the proposed SAFE Act and its potential impact on compounding pharmacies. The discussion explores concerns that the bill could restrict patient access to compounded medications during drug shortages, impose new limitations on 503A pharmacies, and disproportionately affect legitimate compounders while failing to address bad actors. The episode also unpacks the legislation's connection to GLP-1 demand, adverse event reporting, and the bipartisan politics surrounding the bill, while encouraging listeners to stay engaged in APC's advocacy efforts.
More episodes of Pharmacy Podcast Network
- Uplevel your Health with Brown's Gas with George Wiseman | The Holistic Pharmacy Podcast
- Introducing Specialty Care Close to Home | TWIRx
- The Difference a Pharmacy Management System Can Make | Insights: Beyond the Counter
- AI in Pharmacy Standards and Drug Supply Chain Upgrades | TWIRx
- The 2026 McKesson ideaShare Rewind | Part Three
- Insights Beyond the Counter Episode 1 | Outcomes: Insights Beyond the Counter
Explore listener stats, chart rankings, contacts and more on the Pharmacy Podcast Network podcast page.